Plain-English translation of NCT06379646 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is an early-stage trial testing a new treatment called YTS109 cell injection for people with autoimmune diseases that haven't responded well to standard medicines. The study will check whether this treatment is safe and whether it helps reduce disease symptoms. Only 6 people will participate in this first exploratory study.
Many people with autoimmune diseases like lupus, scleroderma, and Sjögren's syndrome continue to suffer even after trying multiple standard treatments. This medication is being explored as a new option for patients whose diseases keep coming back or won't respond to conventional therapy.
You will receive an injection of YTS109 cells as the main treatment. The study will involve regular clinic visits to monitor how safe the treatment is and whether your disease improves. You'll have blood tests and exams to check your organ function and measure your disease activity over time. The exact length and frequency of visits will be determined during the screening process.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China
Sponsor
China Immunotech (Beijing) Biotechnology Co., Ltd.
Collaborators
Shanghai Changzheng Hospital
Enrollment target
~6 participants
Started
April 2024
Primary completion
April 2025
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Huji Xu
Shanghai Changzheng Hospital